Skip to main content

Cytochrome b245 alpha Antibody (CS9) [PE/Atto594]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-40974PEATT594

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-40974PEATT594
Conjugate
Catalog #

Key Product Details

Species Reactivity

Validated:

Human

Applications

ELISA, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunoprecipitation, Western Blot

Label

PE/Atto594 (Excitation = 488 nm, Emission = 627 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # CS9

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Summary for Cytochrome b245 alpha Antibody (CS9) [PE/Atto594]

Immunogen

Cytochrome B245 solubilised in octyl-beta-gluycopyranoside

Specificity

This antibody recognises the light chain of cytochrome B245, also known as p22phox, a subunit of the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase). NADPH oxidase is a membrane-bound enzyme complex in neutrophils that produces the superoxide anion (O2-) by transferring single electrons from NADPH inside the cell across the membrane and coupling them to molecular oxygen. Superoxide is used for the destruction of pathogens. Individuals with defects in NADPH oxidase suffer from chronic granulomatous disease, characterised by severe recurrent infections.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for Cytochrome b245 alpha Antibody (CS9) [PE/Atto594]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Frozen

Optimal dilutions of this antibody should be experimentally determined.

Immunoprecipitation

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined. For optimal results using our Tandem dyes, please avoid prolonged exposure to light or extreme temperature fluctuations. These can lead to irreversible degradation or decoupling. When staining intracellular targets, specific attention to the fixation and permeabilization steps in your flow protocol may be required. Please contact our technical support team at technical@novusbio.com if you have any questions.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: Cytochrome b245 alpha

Alternate Names

cytochrome b light chain, Cytochrome b(558) alpha chain, cytochrome b(558) alpha-subunit, cytochrome b, alpha polypeptide, cytochrome b-245 light chain, cytochrome b-245, alpha polypeptide, Cytochrome b558 subunit alpha, flavocytochrome b-558 alpha polypeptide, Neutrophil cytochrome b 22 kDa polypeptide, p22 phagocyte B-cytochrome, p22phox, p22-PHOX, Superoxide-generating NADPH oxidase light chain subunit

Gene Symbol

CYBA

Additional Cytochrome b245 alpha Products

Product Documents for Cytochrome b245 alpha Antibody (CS9) [PE/Atto594]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Cytochrome b245 alpha Antibody (CS9) [PE/Atto594]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...